Researcher
Karim Vermaelen
- Keywords:immunology, Immuno-oncology, oncology, respiratory medicine
- Disciplines:Immunology not elsewhere classified, Cancer therapy, Cancer biology, Applied immunology, Immunomodulation therapy, Respiratory medicine, Cell therapy, Vaccinology, Oncology not elsewhere classified, Medical transcriptomics
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Internal medicine (Department)
Member
From1 Jan 1998 → 30 Sep 2018
Projects
1 - 10 of 32
- REACTION: A modular mRNA-encoded artificial receptor for focused re-ignition of anti-cancer immune responsesFrom1 Oct 2023 → TodayFunding: BOF - projects
- TARgeted Mrna re-engineering for enhanced Antibody and Cellular immunity (TARMAC)From15 Apr 2023 → 14 Apr 2024Funding: IOF - technology concept exploration
- HIGH-THROUGHPUT, HIGH-SENSITIVITY AND COST-EFFECTIVE MONITORING OF INNATE AND ADAPTIVE IMMUNE RESPONSES AT SINGLE CELL LEVELFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Re-engineering vesicle sorting signals of the mannose-6-phosphate receptor in an mRNA-vaccine approach to enable full anti-cancer T-cell engagementFrom1 Nov 2022 → 31 Oct 2023Funding: Nonprofit institution or equivalents
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Dendritic Cell Immunotherapy In Lung CancerFrom1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- SparXells: Enabling next-generation Dendritic Cell Therapy in Lung Cancer and beyondFrom1 Aug 2021 → 31 Jul 2023Funding: IWT / VLAIO personal funding - innovation mandates
- BioGelator for local immunotherapyFrom15 Jul 2021 → TodayFunding: IOF - technology validation in lab
- Proteomics-derived epitopes for dramatically improved anticancer and antibacterial vaccine developmentFrom1 Jan 2021 → TodayFunding: BOF - projects
- SparXells™ : Enabling Next-Generation Dendritic Cell Therapy in Lung cancer and BeyondFrom15 Oct 2020 → 31 Dec 2022Funding: IOF - technology validation in real environment
Publications
31 - 40 of 71
- The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling(2014)
Authors: Jan Van Deun, Pieter Mestdagh, Raija Sormunen, Veronique Cocquyt, Karim Vermaelen, Marc Bracke, An Hendrix
- A case of isolated cerebral nocardiosis caused by a defect in the IL12-IFNG axis(2014)Volume: 34
Authors: Delfien Bogaert, Veronique Debacker, Steven Callens, Dirk Ommeslagh, Melissa Dullaers, Karim Vermaelen
Pages: S171 - S172 - Use of an integrative classification system and next-generation sequencing strategies for gene identification in common variable immunodeficiency disorder (CVID)(2014)
Authors: Delfien Bogaert, Melissa Dullaers, Filomeen Haerynck, Karim Vermaelen
Number of pages: 1 - The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling(2014)Volume: 3
Authors: Jan Van Deun, Pieter Mestdagh, Raija Sormunen, Lotte Pyfferoen, Karim Vermaelen, Veronique Cocquyt, Marc Bracke, An Hendrix
Number of pages: 1 - A novel Stat1 mutation leading to hyperphosphorylation in a patient with Pneumocystis jjiroveci and chronic mucocutaneous candidiasis(2014)Volume: 34
Authors: Melissa Dullaers, Jens Staal, Sarah Gerlo, Elien Vandermarliere, V Debacker, Victoria Bordon Maria, K De Waele, I Meyts, L Moens, X Bossuyt, et al.
Pages: S443 - S444 - Resistance training in patients with radically treated respiratory cancer: a prospective randomized multi-center study (REINFORCE)(2013)Volume: 49
Authors: Jan Van Meerbeeck, Bihiyga Salhi, C Haenebalcke, S Perez-Bogerd, MD Nguyen, Thomas Malfait, Karim Vermaelen, Veerle Surmont, Georges Van Maele, Eric Derom
Pages: S796 - S797 - Second opinion for thoracic cancer and its impact on diagnosis and treatment strategy: a single institutional series(2013)Volume: 8
Authors: Thomas Malfait, Veerle Surmont, Birgitta I Hiddinga, Karim Vermaelen, Jan Van Meerbeeck
Pages: S1315 - S1315 - Resistance training in patients with radically treated respiratory cancer: mature results of a multi-centre randomised phase 3 trial (REINFORCE)(2013)Volume: 8
Authors: Jan Van Meerbeeck, Bihiyga Salhi, Christel Haenebalcke, Sylvia Perez-Bogerd, May D Nguyen, Thomas Malfait, Karim Vermaelen, Veerle Surmont, Georges Van Maele, Roos Colman, et al.
Pages: S245 - S245 - Effect of radical treatment on exercise capacity and muscle force in patients with intrathoracic cancer(2012)Volume: 7
Authors: Bihiyga Salhi, Charlotte Haenebalcke, S Perez-Bogerd, M Nguyen, Karim Vermaelen, Veerle Surmont, Jan Van Meerbeeck, Eric Derom
Pages: S54 - S54 - Feasibility of epidermal growth factor receptor mutation testing in cytology samples(2012)Volume: 7
Authors: Thomas Malfait, Liesbeth Ferdinande, Jan Van Meerbeeck, D Galdermans, Veerle Surmont, Ramses Forsyth, Karim Vermaelen, Marleen Praet, Kurt Tournoy
Pages: S34 - S35